Table 3. Factors contributing to resistance to CDK4/6 inhibitors.
From: The application and prospect of CDK4/6 inhibitors in malignant solid tumors
Resistance type | Resistance mechanism |
|---|---|
Cyclin-CDK complex increase | CDK6 amplification |
| Â | CCNE1 amplification |
Cyclin D-CDK4/6-Rb pathway regulation | Cyclin D deficiency Rb inactivation or deletion |
| Â | FAT1 loss |
Others | FGFR1 amplification |